论文部分内容阅读
目的观察美沙拉嗪口服联合灌肠治疗溃疡性结肠炎的疗效。方法选择240例轻、中度溃疡性结肠炎患者,随机分为两组:治疗组120例予口服美沙拉嗪,1.0g/次,3次/d,同时给予美沙拉嗪灌肠剂(莎尔福灌肠剂,4g/60ml,用时稀释到100ml)4g/100ml,1次/晚,保留灌肠,8周为1疗程;对照组120例,予口服柳氮磺吡啶片(Alicylazosulfapyridine,SASP)1.0g,4次/d。疗程为8周。结果治疗8周后,治疗组显效率和总有效率明显优于对照组,差异有统计学意义(P<0.05);两组均有不良反应的发生,治疗组发生13例,发生率10.8%,对照组发生68例,发生率56.7%,治疗组明显低于对照组,差异有统计学意义(P<0.05)。结论美沙拉嗪了治疗溃疡性结肠炎临床疗效显著,且不良反应小。
Objective To observe the efficacy of oral mesalazine combined with enema in the treatment of ulcerative colitis. Methods A total of 240 patients with mild to moderate ulcerative colitis were selected and randomly divided into two groups: 120 cases in the treatment group were given mesalazine, 1.0g / time, and 3 times / d, while the mesalazine enema Foe enema, 4g / 60ml diluted with time to 100ml) 4g / 100ml, 1 time / night, enema retention, 8 weeks for a course of treatment; control group of 120 cases, to oral sulfasalazine tablets (Alicylazosulfapyridine, SASP) 1.0g , 4 times / d. The course of treatment is 8 weeks. Results After 8 weeks of treatment, the markedly effective rate and total effective rate in the treatment group were significantly better than those in the control group (P <0.05). Adverse reactions occurred in both groups, with 13 cases in the treatment group, the incidence rate was 10.8% , 68 cases in the control group, the incidence rate was 56.7%, the treatment group was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Mesalazine has a significant clinical effect in the treatment of ulcerative colitis with small adverse reactions.